CLOs on the Move

Innomar Strategies

www.innomar-strategies.com

 
Innomar Strategies, a part of AmerisourceBergen, is Canada`s leading patient support provider for specialty pharmaceuticals. We deliver end-to-end support solutions to improve product access, increase supply chain efficiency and enhance patient care. Strategic consulting, patient assistance programs, nursing and clinical services, and specialty pharmacy and logistics are just a few of our key areas of specialization. We partner closely with manufacturers, healthcare providers, pharmacies and payers to ensure patients have consistent and reliable access to specialty medication. With our integrated approach and commitment to best-in-class care, Innomar Strategies ensures patients are supported throughout their treatment journey every step of the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Brookwood Pharmaceuticals

Brookwood Pharmaceuticals is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Global Pharmaceutical Corp

Global Pharmaceutical Corp is a Chalfont, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmaceutical Credit Corp

Pharmaceutical Credit Corp is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.

Sanofi

Sanofi SA is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the worlds fifth-largest by prescription sales.